Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Fish and Richardson
Merck
Dow
Federal Trade Commission
Covington
Chinese Patent Office
Accenture
Colorcon

Generated: August 17, 2017

DrugPatentWatch Database Preview

Dolasetron mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for dolasetron mesylate and what is the scope of dolasetron mesylate patent protection?

Dolasetron mesylate
is the generic ingredient in one branded drug marketed by Us Pharm Holdings and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for dolasetron mesylate. Three suppliers are listed for this compound.

Summary for Generic Name: dolasetron mesylate

Tradenames:1
Patents:0
Applicants:1
NDAs:2
Drug Master File Entries: see list4
Suppliers / Packagers: see list3
Bulk Api Vendors: see list33
Clinical Trials: see list523
Patent Applications: see list911
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:dolasetron mesylate at DailyMed

Pharmacology for Ingredient: dolasetron mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Pharm Holdings
ANZEMET
dolasetron mesylate
TABLET;ORAL020623-001Sep 11, 1997RXYesNo► Subscribe► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
INJECTABLE;INJECTION020624-002Sep 11, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
INJECTABLE;INJECTION020624-001Sep 11, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
TABLET;ORAL020623-002Sep 11, 1997RXYesYes► Subscribe► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
INJECTABLE;INJECTION020624-003Dec 11, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dolasetron mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings
ANZEMET
dolasetron mesylate
INJECTABLE;INJECTION020624-001Sep 11, 1997► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
TABLET;ORAL020623-001Sep 11, 1997► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
INJECTABLE;INJECTION020624-003Dec 11, 2001► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
TABLET;ORAL020623-002Sep 11, 1997► Subscribe► Subscribe
Us Pharm Holdings
ANZEMET
dolasetron mesylate
TABLET;ORAL020623-002Sep 11, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Express Scripts
Boehringer Ingelheim
Moodys
Harvard Business School
Healthtrust
Fish and Richardson
Chinese Patent Office
Farmers Insurance
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot